Human growth hormone (somatropin) is a 191-amino-acid pituitary polypeptide. Recombinant HGH is bioidentical to the natural hormone and is FDA-approved, for childhood and adult growth-hormone deficiency, HIV-associated wasting, and several pediatric growth disorders.
HGH 191AA Prices
7 vendors · 1 with an issuer-verified COA · cost per IU from $1.87 · checked
Where to buy HGH 191AA: 7 vendors compared
| Vendor | Price | Actions |
|---|---|---|
| $44.99 | Buy HGH 191AA from ZestyRat Research | |
| $447.99 | Buy HGH 191AA from PuraSynth Labs | |
| 5-test panelCOA on fileAverix Laboratories (in-house) · Tested Jul 31, 2026 | $71.99 | Buy HGH 191AA from Averix Labs |
| $112.50 | Buy HGH 191AA from Peptides Costa Rica | |
| 2-test panelVerified COAOptima Labs | $99.0024IU packageChecked Oct 4 | Buy HGH 191AA from Peptides Lab UK |
| $55.24 | Buy HGH 191AA from Atlas Longevity | |
| $67.50 | Buy HGH 191AA from Peptide Express |
Tracked every day
HGH 191AA listing prices, tracked daily
The five cheapest in-stock package prices for HGH 191AA on each collected day, and the vendors that most often held those places.
Five cheapest in-stock package prices per day
Listed package price before coupons, any vial size. This is not the coupon-adjusted lowest 10mg price used to rank the comparison.
- Cheapest$61.38
- 2nd cheapest$70.00
- 3rd cheapest$75.00
- 4th cheapest$99.00
- 5th cheapest$125.00
Vendors most often in the cheapest five
- Peptide Express16 days$75.00+7.1%
- Peptides Costa Rica4 days$125.00last seen Oct 4, 2026+78.6%
- Atlas Longevity2 days$61.38-0.3%
- Averix Labs1 day$79.99last seen Sep 25, 20260.0%
- Peptides Lab UK1 day$99.00last seen Oct 4, 20260.0%
Current market data
HGH 191AA Price Report
A current summary of public listings after the price comparison above. Shipping and tax are not included.
The lowest current cost per IU for HGH 191AA is $1.87 from ZestyRat Research. The median across vendors is $3.75.
- Lowest cost per IU
- $1.87ZestyRat Research
- Median cost per IU
- $3.75One normalized offer per vendor
- Lowest package total
- $35.99ZestyRat Research · package size may differ
- Public COA coverage
- 100%7 of 7 vendors
What the market shows
PeptidePrices found 12 in-stock listings from 7 vendors, checked through Oct 9, 2026. The lowest cost per IU is 50% below the vendor median of $3.75; 3 vendors (43%) fall below that median. 7 of 7 vendors (100%) publish public COA evidence.
A public COA link shows that a vendor publishes testing data. It does not prove that every listed vial has a matching current report. Match the product, strength, batch, and lot before relying on a report.
How this report is calculated
The headline and median use each vendor's lowest cost per IU from listings with a usable package quantity. The lowest package total is shown only as secondary context because package sizes differ. Known public coupon discounts are applied. Shipping, tax, and unverified promotions are excluded.
Research context
What is HGH 191AA? Research, safety, and status
HGH (somatropin/somatotropin) is the body's primary growth hormone, made by the anterior pituitary, and recombinant HGH is the bioidentical pharmaceutical version. Unlike most compounds on this site, it's a long-established FDA-approved drug for defined deficiency states, but it's also widely used off-label for body composition and 'anti-aging', which is where the risk/benefit shifts.
It is prescription-only for its approved uses; off-label use carries legal and health risks. Everything below is research/clinical context, not medical guidance.
Key research takeaways
It works both directly (lipolysis, protein synthesis) and indirectly, by stimulating IGF-1 in the liver and tissues, IGF-1 carries much of the growth/anabolic effect.
The '191AA' label distinguishes true recombinant somatropin from older/inferior 192-aa material; legitimate product is a ~22 kDa, bioidentical protein.
HGH 191AA at a glance
PeptidePrices safety rating
7/10 · FDA-approved (various)
Mechanism
Recombinant human growth hormone; binds GHR; activates JAK2/STAT5 pathway; stimulates IGF-1 production; promotes protein synthesis, lipolysis, gluconeogenesis, and bone growth.
Research areas
GH deficiency; anti-aging; body composition (lean mass, fat loss); pediatric growth disorders; athletic performance; recovery; skin quality.
Regulatory / research status
Research / preclinical only
Half-life
~3.9 hours (SC).
Storage
Lyophilized vial: store at -20°C long-term or 2-8°C short-term, protected from light.
FDA-approved for deficiency, but off-label/high-dose use carries real risk: insulin resistance/diabetes, carpal tunnel, and acromegaly-like changes with chronic use. Contraindicated in active cancer and acute critical illness (increased ICU mortality). Safety ratings summarize published clinical data, adverse-event reporting, and regulatory status. How PeptidePrices rates evidence. Research information only, not medical advice.
Study highlights
- Recombinant human GH (somatropin, 191 amino acids identical to pituitary GH) is approved for adult GHD treatment; a 2022 KIMS registry analysis of 15,809 GH-treated patients over a mean 5.3 years confirmed that overall cancer incidence was comparable to the general population, substantially supporting long-term safety for adult replacement therapy.
- In adults with GHD, somatropin restores normal body composition by reducing fat mass (predominantly visceral) and increasing lean body mass, improves cardiac function, normalizes atherogenic lipid profiles (decreased LDL, increased HDL), and improves quality of life scores, effects confirmed in multiple placebo-controlled trials and systematic review.
- AACE/ACE 2019 guidelines (PMID 31760824) recommend GH replacement in adults with confirmed GHD from pituitary/hypothalamic disease, titrated to normalize IGF-1 for age/sex; doses are substantially lower than performance-enhancing doses historically misused, typically 0.15-0.3 mg/day.
- Clinical Indications for Growth Hormone Therapy (2022 review) catalogues 8 FDA-approved pediatric indications including GHD, Prader-Willi syndrome, Turner syndrome, and chronic renal insufficiency, illustrating the breadth of somatropin's established therapeutic utility beyond simple GH deficiency.
Selected references
- Long-term Safety of Growth Hormone in Adults with Growth Hormone Deficiency: Overview of 15,809 GH-Treated Patients (KIMS) · Journal of Clinical Endocrinology & Metabolism, 2022
- AACE/ACE Guidelines for Management of Growth Hormone Deficiency in Adults and Patients Transitioning from Pediatric to Adult Care · Endocrine Practice, 2019
- Efficacy and Safety of Growth Hormone Treatment in Adults with GHD: A Systematic Review of Studies on Morbidity · Clinical Endocrinology (Oxford), 2014
- Clinical Indications for Growth Hormone Therapy · Advances in Pediatrics, 2022
Related pages